Cienfuegos, December 21 (RHC)-- The Cuban medication CIMAvax-EGF against advanced lung cancer has begun its final stage of clinical trials in the province of Cienfuegos.
Developed by the Havana-based Molecular Immunology Center, the Cuban vaccine is the first registered therapeutic treatment of its kind that generates antibodies against the patient's epidermal growth factor (EGF).
The antibodies generated by the drug inhibit and stop the proliferation of tumor cells, thus stabilizing the pathology, increasing survival and ostensibly improving the patients' quality of life.
Clinical trial lead researcher Yoana Herrera Leyva said that the aim is to assess the response of patients to high and normal doses of the vaccine, in order to customize the treatment.
Cuban Lung Cancer Vaccine Begins Final Stage of Clinical Trials
Related Articles
Commentaries
MAKE A COMMENT
All fields requiredMore Views
- Julian Assange’s t-shirt at Cannes 2025 lists names of 4,986 Palestinian children killed in Israeli genocidal war of aggression
- Cuba and Oman sign a collaboration agreement in the fields of health and medical research
- Columbia University alumni burn diplomas to protest campus repression against pro-Palestinian students
- U.S. government drops oversight of Minneapolis and Louisville police ahead of anniversary of George Floyd’s murder
- Judge allows Palestinian student leader and political prisoner Mahmoud Khalil to hold his infant son for first time